Updated:
Evaxion A/S
Evaxion A/S is a Danish biotech firm using AI for personalized cancer vaccines, with lead candidate EVX-01 in Phase II for melanoma.
Evaxion A/S
Evaxion A/S was founded to harness artificial intelligence for immunotherapy development, targeting cancers like melanoma and non-small cell lung cancer. The firm's wealth origin is not publicly tied to a single family; it is a publicly listed entity on the Nasdaq Copenhagen exchange. The company's strategy centers on the AI-Immunology platform, which predicts unique tumor mutations for personalized vaccines. Core asset classes include early-stage clinical assets, with EVX-01 in Phase II and EVX-02 in Phase I/II. Known pipeline candidates also address bladder and ovarian cancers. Geographically, operations are primarily in Denmark, with clinical activities across Europe and the United States. Public records indicate Evaxion has fewer than 50 employees, with key executives including CEO Lars Wagner. The firm maintains no disclosed adjacent vehicles or operating businesses beyond its core R&D focus. One recent milestone is the September 2023 announcement of positive Phase II data for EVX-01 in melanoma patients (per Evaxion, September 2023). A structural differentiator is Evaxion's reliance on AI for end-to-end neoantigen prediction, a model that reduces vaccine design timelines from months to weeks. Its public company status also means governance separates it from family-office structures, instead accountable to shareholders and regulatory bodies.
General information
Firm type
Other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at Evaxion?
The firm is publicly traded (Evaxion A/S on Nasdaq Copenhagen), so strategic and investment decisions are overseen by its Board of Directors and executive management, led by CEO Lars Wagner. Day-to-day R&D allocation is managed by the executive team. (public record)
How does Evaxion source proprietary deal flow?
Evaxion's pipeline is internally generated through its AI-Immunology platform, which analyzes patient tumor data to identify neoantigens. The firm does not typically acquire external assets but rather develops candidates from its own discovery engine. (per Evaxion investor materials)
Is Evaxion structured as a single family office or does it operate more like a biotech firm?
Evaxion is a publicly listed biotechnology company, not a family office. It operates as a clinical-stage drug developer with a governance structure typical of listed life sciences firms, including a board and shareholder oversight.
Does Evaxion participate in fund commitments or only direct R&D?
Evaxion does not act as an investment fund; it is an operating company that directly allocates capital to its R&D programs and clinical trials. It does not make external fund commitments or co-investments as a financial investor.
What investment stages does Evaxion typically target?
Evaxion targets early-stage drug development, from preclinical through Phase II clinical trials. Its lead program EVX-01 is in Phase II, with earlier-stage programs in Phase I and preclinical testing. (public record)
Which sectors does Evaxion explicitly avoid?
The firm focuses exclusively on oncology immunotherapy and does not invest in non-biotech assets, real estate, or financial instruments. Its work is concentrated on AI-driven vaccine design for cancer.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: